|Bid||13.45 x 2200|
|Ask||13.46 x 1400|
|Day's Range||13.07 - 13.51|
|52 Week Range||1.39 - 14.55|
|Beta (5Y Monthly)||3.25|
|PE Ratio (TTM)||N/A|
|Earnings Date||May 11, 2020|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||25.00|
The “Mad Money” host says, ‘Never underestimate the power of enthusiastic buyers who do not know what they’re doing.”
Blame the Fed? No. I'm reserving my wrath for the clueless buyers who appear to have taken a permanent intellectual summer vacation.
Shares of Sorrento Therapeutics (NASDAQ: SRNE) rocketed 31% higher on Tuesday, following bullish comments from a respected analyst. H.C. Wainwright analyst Raghuram Selvaraju reiterated his buy rating on Sorrento's stock and boosted his target price from $24 to $30. Selvaraju said he is intrigued by the potential of a new rapid diagnostic test that Sorrento recently licensed from Columbia University that can reportedly detect the SARS-CoV-2 virus in as little as 30 minutes using saliva samples rather than unpleasant nasal swabs.